Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X (formerly Twitter) and LinkedIn.WALTHAM, Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on novel mechanisms in oncology at the Citi 2024 Global Healthcare Conference on Thursday, December 5, 2024 at 11:00 a.m. ET.
馬薩諸塞州沃爾瑟姆，2024年11月27日 /PRNewswire/ -- syndax pharmaceuticals（納斯達克：SNDX），是一家開發創新癌症療法管線的商業階段生物製藥公司，今天宣佈，syndax的首席執行官Michael A. Metzger將於2024年12月5日（星期四）上午11:00參與在花旗2024全球醫療保健大會上關於腫瘤學中新機制的圓桌討論。
A live webcast of the panel can be accessed from the Investor section of the Company's website at , where a replay will also be available for a limited time.
可通過公司網站的投資者部分訪問該小組的實時網絡廣播，回放也將在有限的時間內提供。
About Syndax
關於Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on X (formerly Twitter) and LinkedIn.
syndax pharmaceuticals是一家商業階段的生物製藥公司，正在開發創新的癌症治療藥物。公司的管線重點包括Revuforj（revumenib），這是一種FDA批准的menin抑制劑，以及Niktimvo（axatilimab-csfr），這是一種FDA批准的單克隆抗體，能阻斷集落刺激因子1（CSF-1）受體。憑藉我們對重新構想癌症護理的承諾，Syndax正致力於釋放其管線的全部潛力，並在治療的各個環節進行多項臨床試驗。欲了解更多信息，請訪問或在X（前稱Twitter）和LinkedIn上關注公司。
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
syndax pharmaceuticals 聯繫方式
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
電話 781.684.9827
SNDX-G
SNDX-G
SOURCE Syndax Pharmaceuticals, Inc.
消息來源：Syndax Pharmaceuticals，Inc。
